NCT04783051View on ClinicalTrials.gov

Comparison of ISTp- PYRAMAX-US-RDT to IPTp-SP to Prevent Malaria in Pregnant Women in DRC (ULTRAPYRAPREG)

PHASE3CompletedINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

May 6, 2021

Primary Completion Date

June 22, 2022

Study Completion Date

June 22, 2022

Conditions
Malaria in Pregnancy
Interventions
DRUG

Sulfadoxine pyrimethamine

Intermittent Preventive Treatment in pregnant women with Sulfadoxine-Pyrimethamine

DRUG

Pyramax

Intermittent screening using ultra-sensitive malaria Rapid Diagnostic test and treatment using Pyronaridine - Artesunate (PYRAMAX®)

Trial Locations (1)

Unknown

Maternité Esengo, Kinshasa

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

European and Developing Countries Clinical Trials Partnership (EDCTP)

OTHER_GOV

collaborator

Novartis

INDUSTRY

lead

University of Kinshasa

OTHER

NCT04783051 - Comparison of ISTp- PYRAMAX-US-RDT to IPTp-SP to Prevent Malaria in Pregnant Women in DRC (ULTRAPYRAPREG) | Biotech Hunter | Biotech Hunter